Bsense Announces the Clinical Candidate Nomination of BSEN760, a Novel Dual Kv7.2/3 and TRPV1 Modulator, to Unlock a New Approach to Dampening Sensory Hyperexcitability for Chronic Pain Treatment
Retrieved on:
Tuesday, December 5, 2023
BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1.
Key Points:
- BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1.
- The dual mechanism of action (MOA) of BSEN760 underlies the compound’s exquisite potency and synergistic activity in dampening sensory neuron hyperexcitability.
- As such, BSEN760 may enter the market with comparable, potentially better, efficacy vs. SOC, and a much improved safety profile.
- These, and other data, support the Company’s efforts toward full preclinical development of BSEN760 and IND submission by Q1 2025.